Cardiology Headline News

In patients with heart failure and mildly reduced or preserved ejection fraction, finerenone reduced risk for CV death and worsening HF by 16% compared with placebo, researchers reported at the European Society of Cardiology Congress.

Transcatheter mitral valve repair in addition to medical therapy led to a lower rate of CV events and hospitalizations and better health status compared with medical therapy alone for patients with HF and moderate to severe mitral regurgitation.

A polypill containing multiple blood pressure-lowering drugs may be an effective solution to addressing both uncontrolled hypertension and polypharmacy causing non-adherence to antihypertensive medications, speakers reported.

The timing of when a patient takes their blood pressure medication does not appear to matter for reducing CV event risk, according to two trials and a meta-analysis presented at the European Society of Cardiology Congress.

In an analysis of deaths of patients with obesity but not diabetes from the SELECT trial, those assigned semaglutide 2.4 mg had reduced risk for death from COVID-19 compared with those assigned placebo.

Clinicians will gather for AIMed24 to meet with industry leaders and innovators and attend keynotes and workshops to discuss the future of AI implementation in medicine, according to information from the meeting organizers.

Discontinuation of renin-angiotensin system inhibitor therapy before major noncardiac surgery did not appear to affect postoperative outcomes vs. treatment continuation, a speaker reported.

In the ABYSS trial, a strategy of interrupting long-term beta-blocker treatment was not noninferior to continued use for the primary composite outcome of death, myocardial infarction, stroke or hospitalization for CV reasons.

Among patients with transthyretin amyloidosis with cardiomyopathy, vutrisiran, an RNA interference agent, reduced risk for death and recurrent CV events compared with placebo, according to the results of the HELIOS-B trial.

Attempts to curtail prior authorizations for patients insured by Medicare Advantage plans have failed in back-to-back legislative sessions in 2019 and 2021, but a new bill has some experts hopeful that the third time is a charm.